Chartmaster
18 시간 전
CBD Life Sciences Inc. (CBDL) Announces New Delta-8 100MG Gummies Designed to Support Individuals Living With Alzheimer’s
Targeting a booming $6 billion U.S. edibles market with a projected $3 million in first-year revenue, CBDL delivers an innovative solution for Alzheimer's care.
SCOTTSDALE, ARIZONA / ACCESSWIRE / December 3, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in cannabinoid innovation, proudly announces the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions.
CBD Life Sciences' entry into this specialized segment of the $6 billion U.S. edibles market positions the company as a pioneer in creating products tailored to an underserved demographic. As the population ages and awareness of natural alternatives grows, Delta-8 products are rapidly gaining traction as effective solutions for managing symptoms associated with Alzheimer's and related conditions.
A Product Born from Real Needs and Scientific Innovation
The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.
Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief.
Lisa Nelson, President and CEO of CBD Life Sciences Inc., shared:
"Our mission has always been to create products that genuinely improve lives. With our Delta-8 Gummies, we're addressing a critical gap in Alzheimer's care by offering a natural, effective alternative that families and caregivers can trust. This launch also marks an exciting growth opportunity for our company as we expand into a high-demand market segment."
Revenue and Growth Potential
The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional $3 million in revenue within its first year, as CBD Life Sciences continues to meet the rising interest in cannabinoid-based solutions for elderly care.
The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a 300% increase in cannabinoid use among individuals aged 65 and older over the past decade. This demographic is increasingly turning to natural products like Delta-8 for their ability to support physical and cognitive health without the side effects often associated with pharmaceuticals.
Meeting the Needs of an Underserved Market
CBD Life Sciences' Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy.
The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care.
CBD Life Sciences: Setting the Standard in Innovation
The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a 1405.46% increase in revenue, driven by its commitment to delivering high-quality, innovative products that resonate with consumers.
This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a forward-thinking company dedicated to developing and commercializing cannabinoid-based health and wellness solutions. With a diverse product portfolio that includes pain relief creams, nano CBD beverages, and Delta-8 edibles, CBD Life Sciences aims to improve lives while delivering exceptional value to its shareholders.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
© Copyright 2024 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/CBDL/news/story?e&id=3063832
AveragePenny
19 시간 전
$CBDL CBD Life Sciences Inc. (CBDL) Announces New Delta-8 100MG Gummies Designed to Support Individuals Living With Alzheimer’s
https://www.accesswire.com/949292/cbd-life-sciences-inc-cbdl-announces-new-delta-8-100mg-gummies-designed-to-support-individuals-living-with-alzheimers
Targeting a booming $6 billion U.S. edibles market with a projected $3 million in first-year revenue, CBDL delivers an innovative solution for Alzheimer's care.
SCOTTSDALE, ARIZONA / ACCESSWIRE / December 3, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in cannabinoid innovation, proudly announces the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions.
CBD Life Sciences' entry into this specialized segment of the $6 billion U.S. edibles market positions the company as a pioneer in creating products tailored to an underserved demographic. As the population ages and awareness of natural alternatives grows, Delta-8 products are rapidly gaining traction as effective solutions for managing symptoms associated with Alzheimer's and related conditions.
A Product Born from Real Needs and Scientific Innovation
The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.
Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief.
Lisa Nelson, President and CEO of CBD Life Sciences Inc., shared:
"Our mission has always been to create products that genuinely improve lives. With our Delta-8 Gummies, we're addressing a critical gap in Alzheimer's care by offering a natural, effective alternative that families and caregivers can trust. This launch also marks an exciting growth opportunity for our company as we expand into a high-demand market segment."
Revenue and Growth Potential
The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional $3 million in revenue within its first year, as CBD Life Sciences continues to meet the rising interest in cannabinoid-based solutions for elderly care.
The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a 300% increase in cannabinoid use among individuals aged 65 and older over the past decade. This demographic is increasingly turning to natural products like Delta-8 for their ability to support physical and cognitive health without the side effects often associated with pharmaceuticals.
Meeting the Needs of an Underserved Market
CBD Life Sciences' Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy.
The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care.
CBD Life Sciences: Setting the Standard in Innovation
The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a 1405.46% increase in revenue, driven by its commitment to delivering high-quality, innovative products that resonate with consumers.
This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry.
Chartmaster
2 주 전
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis DispensaryPress Release | 11/19/2024
With the New York cannabis market projected to surpass $5 billion by 2027, this acquisition positions CBDL for exponential revenue growth and expanded market dominance.
SCOTTSDALE, AZ / ACCESSWIRE / November 19, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneering force in the CBD and cannabis industries, is proud to announce the signing of a pivotal Letter of Intent (LOI) to acquire an interest in a cannabis dispensary located in New York. The dispensary, purchased from Market Wave Capital, LLC, is expected to generate $8 million in annual revenue once operational and marks a transformative moment in CBDL's journey toward industry dominance. Pending financing and state regulatory approvals, the dispensary is slated to open its doors within six months, ushering in a new chapter of accelerated growth and profitability.
A Game-Changing Move in a Booming Industry
The global marijuana dispensary market is on a meteoric rise, projected to grow at a compound annual growth rate (CAGR) of 25.5%, with revenues anticipated to surpass $73.6 billion by 2030. New York, a burgeoning hub for cannabis consumption and sales, presents unparalleled opportunities for growth, thanks to progressive legislation and a rapidly expanding consumer base.
"This acquisition is a monumental milestone for CBD Life Sciences and a testament to our aggressive growth strategy," said Lisa Nelson, President and CEO of CBDL. "The dispensary's location in New York positions us at the epicenter of one of the fastest-growing cannabis markets in the world. With projected revenues of $8 million annually, this venture is set to deliver significant value to our shareholders while opening new doors for expansion into adjacent markets."
Why This Matters for CBDL and Its Investors
The dispensary's strategic location in New York provides immediate access to a cannabis market projected to exceed $5 billion in annual sales by 2027. CBDL is seizing this opportunity at a critical juncture in the industry's evolution, aligning itself with the broader movement toward cannabis legalization and normalization.
For investors, this development underscores the company's ability to execute high-impact initiatives while navigating a highly competitive and regulated market. The acquisition not only bolsters CBDL's revenue potential but also establishes a foundation for future ventures in high-demand sectors, including recreational, medical, and hybrid cannabis markets.
Furthermore, the dispensary is expected to serve as a gateway for CBDL to introduce its own product lines into a retail setting, creating cross-promotional opportunities and fostering brand loyalty among a rapidly growing customer base.
Revenue, Growth, and a Vision for the Future
With potential revenues of $8 million annually, this acquisition is a significant leap forward for CBDL's financial profile. Beyond the immediate economic impact, this strategic move sets the stage for:
Market Diversification: The dispensary adds a robust revenue stream, complementing CBDL's existing portfolio of CBD products.
Future Expansion: Establishing a foothold in New York lays the groundwork for scaling operations to other states as cannabis legalization continues to gain momentum.
Enhanced Shareholder Value: The dispensary's profitability will drive returns for current shareholders while making CBDL an attractive investment for new stakeholders.
Strategic Significance
The acquisition reflects CBDL's forward-thinking approach to growth, as the company positions itself at the intersection of opportunity and innovation. By tapping into the New York cannabis market, CBDL is not just diversifying its portfolio but also creating synergies between its dispensary operations and its existing product lines, including pain creams, nano CBD coffee creamers, and more.
Additionally, the dispensary aligns with CBDL's mission to provide high-quality cannabis solutions while embracing consumer trends and regulatory changes. This move reinforces CBDL's standing as a company that is not only thriving in the present but also building for the future.
A Call to Shareholders and Future Investors
"This is only the beginning," added Nelson. "CBDL's strategic direction is clear: growth, innovation, and value creation. The dispensary will act as a springboard for broader ventures, and we are just getting started in leveraging the opportunities this industry offers."
CBDL invites shareholders and prospective investors to join us on this journey as we solidify our position as a leader in the cannabis and CBD industries. This acquisition underscores our commitment to seizing high-value opportunities and delivering long-term value to our shareholders. More updates to come!
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and cannabis industries, with a mission to enhance lives through premium-quality products and groundbreaking market strategies. The company's diverse portfolio and forward-thinking initiatives position it as a dynamic force in one of the most exciting and fast-growing industries in the world.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Closes-on-LOI-for-Potential-8-Million-Revenue-Cannabis-Dispensary?id=459587
Hot Features
프리미엄
실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
packerfan9
11 시간 전
MahinAgency
12 시간 전
RedSox04
19 시간 전
firebag1
2 주 전
Rainer
2 주 전
stealofadeal
3 주 전
